Parties
Identify full legal names, contact points, and authorized signatories for each business to ensure proper attribution and enforceability of obligations under the agreement.
An MTBA protects proprietary assets, clarifies permitted uses and IP ownership of derivatives, assigns handling and biosafety responsibilities, and limits commercial and regulatory exposure. It makes obligations explicit—confidentiality, indemnities, insurance, reporting, and disposal—which reduces commercial risk and supports compliance with export, biosafety, and contractual rules.
Common parties include material providers, commercial recipients, third-party testing labs, and sometimes academic collaborators in joint projects.
Agreements also name authorized signatories, project leads, and compliance officers who oversee handling, storage, and reporting obligations.
In-house or outside counsel for the supplying company reviews MTBA language to protect IP, limit warranty exposure, confirm export and biosafety compliance, and negotiate indemnities, insurance, and return/destruction obligations before approval.
Recipient R&D or operations managers verify handling, storage conditions, permits, and chain-of-custody processes; they confirm that staff training and facilities meet the provider's biosafety and contractual requirements prior to acceptance.
Identify full legal names, contact points, and authorized signatories for each business to ensure proper attribution and enforceability of obligations under the agreement.
Provide a precise description (strain, lot, composition, quantity, storage) and any biosafety classifications or handling instructions to avoid ambiguity and safety violations.
Specify exactly what activities the recipient may perform (research, testing, evaluation, commercial development) and explicitly exclude unpermitted activities like resale or human use if intended.
Define ownership and licensing of derivatives, improvements, and data generated from the material, including rights to commercialize and obligations to disclose inventions.
State confidentiality obligations, duration, permitted disclosures, and carve-outs, and require secure handling of nonpublic technical information tied to materials.
Allocate risk via disclaimers, warranties, insurance requirements, and mutual indemnities to address product safety, misuse, and third-party claims arising from material use.
| Field | Configuration |
|---|---|
| Upload Template | PDF or DOCX with mapped signature fields |
| Assign Signers | Provider then recipient order as needed |
| Authentication | Email, SMS code, or stronger methods |
| Retention Policy | Set storage period per company policy |
Ensure your eSignature platform supports required authentication, document formats, and integrations with business systems used to manage MTBAs.
Choose platform features (audit trail, conditional fields, API access) that match legal, operational, and records-retention requirements.
1–4 weeks depending on risk and counsel availability
3–10 business days for internal sign-off
Allow 3–14 days for specialized transport
As specified in agreement, often 30–90 days
Typically 30–90 days written notice
Template populated with material and party data.
Legal and operations review for compliance.
Signatures obtained and audit trail recorded.
Shipment completed and receipt documented.
A startup supplies a bacterial strain for CRO testing
A manufacturer sends prototype parts to a contract testing lab
| signNow | DocuSign | Adobe Sign | PandaDoc | HelloSign | |
|---|---|---|---|---|---|
| Starting Price | $8/user/mo | $15/user/mo | $14/user/mo | $19/user/mo | $15/user/mo |
| Free Trial | 7-day free trial | Varies | Varies | Varies | Varies |
| Bulk Send | Yes | Yes | Yes | Yes | No |
| Audit Trail | Yes | Yes | Yes | Yes | Yes |
| HIPAA Compliant | Yes (BAA available) | Yes | Yes | No | No |
| Envelope Cap | No cap | 100 envelopes/user/year | Varies by plan | Varies by plan | Varies by plan |